Quest Diagnostics Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Quest Diagnostics Inc's ROA in the second quarter of 2026?
Quest Diagnostics Inc achieved a return on average assets (ROA) of 6.7 % in its second quarter of 2026, which is below Quest Diagnostics Inc's average return on assets, which stands at 8.13%.

ROA has improved compared to 6.57% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 134 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 944, from total ROA ranking in the first quarter of 2026 at 1109.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	6.66 %	6.39 %	6.04 %	4.94 %	20.27 %
Y / Y Net Income Change	12.84 %	12.34 %	8.47 %	9.28 %	23.33 %
Net Income (TTM) in million	1,113	1,075	1,046	1,026	1,004
Return On Assets (TTM)	6.7 %	6.57 %	6.5 %	6.47 %	6.4 %
DGX's Total Ranking	# 944	# 1109	# 961	# 981	# 1014
Total Assets (TTM) in million	17,033	16,807	16,439	16,197	15,969
Seq. Total Assets Change	1.34 %	2.24 %	1.49 %	1.43 %	1.09 %
Seq. Net Income Change	26.52 %	3.13 %	-1.16 %	-12.5 %	25.96 %

DGX's 5 Years Annual ROA >> Back to DGX Management Effectiveness >> Compare DGX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 4
Sector	# 135
Overall	# 926

Return On Assets Statistics
High	Average	Low
17.03 %	8.13 %	4.28 %
(Jun 30 2021)		(Dec. 31, 2007)

Financial Statements
Quest Diagnostics Inc's Assets	$ 17,033 million	DGX's Balance sheet
Quest Diagnostics Inc's Income	$ 334 million	Quarterly DGX's Income Statement
DGX's Income by Division		See DGX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	5.54 %	15.51 %	9.53 %	-5.86 %	-3.04 %
Total Assets in million	16,361	15,502	13,420	12,252	13,014
Y / Y Net Income Change	13.57 %	1.43 %	-10.54 %	-51.2 %	38.76 %
Net Income in million	1,046	921	908	1,015	2,080
Annual Return On Assets	6.39 %	5.94 %	6.77 %	8.28 %	15.98 %

DGX's 5 Years Annual ROA >> Back to DGX Management Effectiveness >> Compare DGX ROA to its Competitors

Comment on DGX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 6.39 % compared to prior year, due to annual net income growth of 13.57 % to $1,046.00 million, while value of Quest Diagnostics Inc's overall assets grew just by 5.54 % to $16,361.00 million, compared to $16,361.00 a year before.

More Return On Assets Ratios
DGX's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DGX's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DGX's Competitors
Subscribers only: Roa for Quest Diagnostics Inc's Suppliers
Subscribers only: Return On Assets for DGX's Customers

You may also want to know
DGX's Roi	DGX's Inventory Turnover Ratio	DGX's Growth Rates	DGX's Dividend Comparisons
	DGX's Profitability Ratios	DGX's Asset Turnover Ratio	DGX's Dividend Growth
DGX's Roe	DGX's Valuation Ratios	DGX's Financial Strength Ratios	DGX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %
Msa Safety Inc	12.23 %

Date modified: 2026-09-08T17:24:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.